Free signup for more
- Track your favorite companies
- Receive email alerts for new filings
- Personalized dashboard of news and more
- Access all data and search results
Filing tables
Filing exhibits
Associated filings
- 17 May 24 424B5 Prospectus supplement for primary offering
- 14 May 24 424B5 Prospectus supplement for primary offering
- 9 May 24 424B5 Prospectus supplement for primary offering
- 6 May 24 424B5 Prospectus supplement for primary offering
- 2 May 24 424B5 Prospectus supplement for primary offering
- 2 May 24 424B5 Prospectus supplement for primary offering
- 2 May 24 424B5 Prospectus supplement for primary offering
- 15 Apr 24 424B5 Prospectus supplement for primary offering
- 12 Apr 24 424B5 Prospectus supplement for primary offering
- 11 Apr 24 424B5 Prospectus supplement for primary offering
- 9 Apr 24 424B5 Prospectus supplement for primary offering
- 19 Mar 24 424B5 Prospectus supplement for primary offering
- 30 Nov 23 EFFECT Notice of effectiveness
-
2 Nov 23 S-3 Shelf registration
ALLR similar filings
Filing view
External links
Exhibit 23.1
CONSENT OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM
We consent to the incorporation by reference in this Registration Statement on Form S-3 and related Prospectus of Allarity Therapeutics, Inc. of our report dated March 9, 2023, relating to the consolidated financial statements of Allarity Therapeutics, Inc. appearing in the Annual Report on Form 10-K of Allarity Therapeutics, Inc. for the year ended December 31, 2022.
We also consent to the reference to our firm under the heading “Experts” in such Prospectus.
/s/ Wolf & Company, P.C. |
Wolf & Company, P.C.
Boston, Massachusetts
November 2, 2023